KR20220016124A - 벤조트리아졸 유도체 - Google Patents
벤조트리아졸 유도체 Download PDFInfo
- Publication number
- KR20220016124A KR20220016124A KR1020217042003A KR20217042003A KR20220016124A KR 20220016124 A KR20220016124 A KR 20220016124A KR 1020217042003 A KR1020217042003 A KR 1020217042003A KR 20217042003 A KR20217042003 A KR 20217042003A KR 20220016124 A KR20220016124 A KR 20220016124A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- benzo
- dimethyl
- triazol
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(OC(*)(*)CN(C)C1)=C1*(I)=C(*=C)C(*)=* Chemical compound C*(OC(*)(*)CN(C)C1)=C1*(I)=C(*=C)C(*)=* 0.000 description 14
- DIXWUHAVSHEXCB-UHFFFAOYSA-N BrCc1cc2ncccc2cc1Br Chemical compound BrCc1cc2ncccc2cc1Br DIXWUHAVSHEXCB-UHFFFAOYSA-N 0.000 description 1
- ZGAJSGGORHAXPM-UHFFFAOYSA-N C(C1)C11Oc2cc3cccnc3cc2CNC1 Chemical compound C(C1)C11Oc2cc3cccnc3cc2CNC1 ZGAJSGGORHAXPM-UHFFFAOYSA-N 0.000 description 1
- UNYKMORWROFNIS-HJWRWDBZSA-N CC(C(C(C(C)(C)C(CO)=O)c1cc(CNCc2cnc(C)c(/C=C\C)c2O)c(C)cc1)C=C1)c2c1[n](C)nn2 Chemical compound CC(C(C(C(C)(C)C(CO)=O)c1cc(CNCc2cnc(C)c(/C=C\C)c2O)c(C)cc1)C=C1)c2c1[n](C)nn2 UNYKMORWROFNIS-HJWRWDBZSA-N 0.000 description 1
- ZEIPNOGLLAOLJL-IJFXDBOGSA-O CC(C)(C(C1=CC=C(C)C(CN(Cc2cc(nccc3)c3cc2O2)C/C2=C/C)C1)c(cc1)c(C)c2c1[n](C)n[nH+]2)C(OC)=O Chemical compound CC(C)(C(C1=CC=C(C)C(CN(Cc2cc(nccc3)c3cc2O2)C/C2=C/C)C1)c(cc1)c(C)c2c1[n](C)n[nH+]2)C(OC)=O ZEIPNOGLLAOLJL-IJFXDBOGSA-O 0.000 description 1
- YNKMHALYWVYIDZ-UHFFFAOYSA-N CC(C)(C(c1cc(CNCc(c(O)c2)cc3c2SCC3)c(C)cc1)c(cc1)c(C)c2c1[n](C)nn2)C(O)=O Chemical compound CC(C)(C(c1cc(CNCc(c(O)c2)cc3c2SCC3)c(C)cc1)c(cc1)c(C)c2c1[n](C)nn2)C(O)=O YNKMHALYWVYIDZ-UHFFFAOYSA-N 0.000 description 1
- PNPSFTXLSNRKHV-UHFFFAOYSA-N CC(C)(C(c1cc(CNCc2cc3ccncc3cc2O)c(C)cc1)c(cc1)c(C)c2c1[n](C)nn2)C(OC)=O Chemical compound CC(C)(C(c1cc(CNCc2cc3ccncc3cc2O)c(C)cc1)c(cc1)c(C)c2c1[n](C)nn2)C(OC)=O PNPSFTXLSNRKHV-UHFFFAOYSA-N 0.000 description 1
- ZPVMOACFULSAAH-UHFFFAOYSA-N CC(C)(C)OC(NCc(ccc1c2ccnc1)c2O)=O Chemical compound CC(C)(C)OC(NCc(ccc1c2ccnc1)c2O)=O ZPVMOACFULSAAH-UHFFFAOYSA-N 0.000 description 1
- PCZICMVKNDBKLL-UHFFFAOYSA-N CC(C)(C)OC(NCc(ncc1c2cccc1)c2O)=O Chemical compound CC(C)(C)OC(NCc(ncc1c2cccc1)c2O)=O PCZICMVKNDBKLL-UHFFFAOYSA-N 0.000 description 1
- FBJZYFUGZKHRFW-UHFFFAOYSA-N CC(C)(C)OC(NCc1cc(CCCC2)c2cc1O)=O Chemical compound CC(C)(C)OC(NCc1cc(CCCC2)c2cc1O)=O FBJZYFUGZKHRFW-UHFFFAOYSA-N 0.000 description 1
- FNTBJJSZXCVFML-UHFFFAOYSA-N CC(C)(C)OC(NCc1cc(cncc2)c2cc1O)=O Chemical compound CC(C)(C)OC(NCc1cc(cncc2)c2cc1O)=O FNTBJJSZXCVFML-UHFFFAOYSA-N 0.000 description 1
- VHPQKMQTEWJGEB-UHFFFAOYSA-N CC(C)(CNCc(cc1N=CCCc1c1)c1[Br]=C)O Chemical compound CC(C)(CNCc(cc1N=CCCc1c1)c1[Br]=C)O VHPQKMQTEWJGEB-UHFFFAOYSA-N 0.000 description 1
- XTNWDHDVNBZRGV-UHFFFAOYSA-N CC1C(CNCC(C=C2N(C)N=CC2C2)=C2O)=CC(C(C(C)(C)C(OC)=O)c(cc2)c(C)c3c2[n](C)nn3)=CC1 Chemical compound CC1C(CNCC(C=C2N(C)N=CC2C2)=C2O)=CC(C(C(C)(C)C(OC)=O)c(cc2)c(C)c3c2[n](C)nn3)=CC1 XTNWDHDVNBZRGV-UHFFFAOYSA-N 0.000 description 1
- VNROXFRQWLRUPW-UHFFFAOYSA-N CCCC(CN(Cc1c(C)ccc(C(C(C)(C)C(OC)=O)c(cc2)c(C)c3c2[n](C)nn3)c1)Cc1c2)Oc1cc1c2nccc1 Chemical compound CCCC(CN(Cc1c(C)ccc(C(C(C)(C)C(OC)=O)c(cc2)c(C)c3c2[n](C)nn3)c1)Cc1c2)Oc1cc1c2nccc1 VNROXFRQWLRUPW-UHFFFAOYSA-N 0.000 description 1
- POYLORDJWZTYDN-UHFFFAOYSA-N CCCc(c(C)c1)cc(CNC(OC(C)(C)C)=O)c1O Chemical compound CCCc(c(C)c1)cc(CNC(OC(C)(C)C)=O)c1O POYLORDJWZTYDN-UHFFFAOYSA-N 0.000 description 1
- IOSYSBZMALWWDP-ZBNGPTGXSA-N CC[C@H](C1)O/C(/CC)=C/C(/NC(OC(C)(C)C)=O)=C(/C)\C=C\CN1OC(c1ccccc1)=O Chemical compound CC[C@H](C1)O/C(/CC)=C/C(/NC(OC(C)(C)C)=O)=C(/C)\C=C\CN1OC(c1ccccc1)=O IOSYSBZMALWWDP-ZBNGPTGXSA-N 0.000 description 1
- RJWCOQVQVTWYJQ-SNVBAGLBSA-N CC[C@H](CN(C1)C(OC(C)(C)C)=O)Oc(cc2)c1nc2Cl Chemical compound CC[C@H](CN(C1)C(OC(C)(C)C)=O)Oc(cc2)c1nc2Cl RJWCOQVQVTWYJQ-SNVBAGLBSA-N 0.000 description 1
- QOJNOXBFJRRNOE-WMOOXEQMSA-N CC[C@H](CN(CCC1=CC(C(C(C)(C)C(O)=O)C(/C=C\c2cnn[n]2C)=C)=CCC1(C)C)C1)Oc2c1cnc1ccccc21 Chemical compound CC[C@H](CN(CCC1=CC(C(C(C)(C)C(O)=O)C(/C=C\c2cnn[n]2C)=C)=CCC1(C)C)C1)Oc2c1cnc1ccccc21 QOJNOXBFJRRNOE-WMOOXEQMSA-N 0.000 description 1
- AGLNVVRYEGQVDV-JSAORFSISA-N CC[C@H](CN(Cc(cc(C(C(C)(C)C(OC)=O)c(cc1)c(C)c2c1N(C)N(C)N2)cc1)c1OC)Cc1c2)Oc1cc1c2nccc1 Chemical compound CC[C@H](CN(Cc(cc(C(C(C)(C)C(OC)=O)c(cc1)c(C)c2c1N(C)N(C)N2)cc1)c1OC)Cc1c2)Oc1cc1c2nccc1 AGLNVVRYEGQVDV-JSAORFSISA-N 0.000 description 1
- KRPNSJQWXRXSNL-YDVOUYDTSA-N CC[C@H](CN(Cc1cc(C(C(C)(C)[C@H](N)O)c(cc2)c(C)c3c2[n](C)nn3)ccc1)Cc1c2)Oc1cc1c2N=CCC1 Chemical compound CC[C@H](CN(Cc1cc(C(C(C)(C)[C@H](N)O)c(cc2)c(C)c3c2[n](C)nn3)ccc1)Cc1c2)Oc1cc1c2N=CCC1 KRPNSJQWXRXSNL-YDVOUYDTSA-N 0.000 description 1
- QMKPYZWJXSBPIC-CQSZACIVSA-N CC[C@H](CNC(OC(C)(C)C)=O)Oc(c(C(OC)=O)c1)cc2c1c(F)ccc2 Chemical compound CC[C@H](CNC(OC(C)(C)C)=O)Oc(c(C(OC)=O)c1)cc2c1c(F)ccc2 QMKPYZWJXSBPIC-CQSZACIVSA-N 0.000 description 1
- DKZVDZZHAVXNHG-AMLLJQFGSA-N CC[C@H]1Oc2cc(cccc3)c3cc2CN(Cc2cc(C(C(C)(C)C(O)=O)c(cc3)c(C)c4c3N(C)N(C)N4)ccc2C)C1 Chemical compound CC[C@H]1Oc2cc(cccc3)c3cc2CN(Cc2cc(C(C(C)(C)C(O)=O)c(cc3)c(C)c4c3N(C)N(C)N4)ccc2C)C1 DKZVDZZHAVXNHG-AMLLJQFGSA-N 0.000 description 1
- ILIQWIIQCXGTJW-GFCCVEGCSA-N CC[C@H]1Oc2cc3cccc(Cl)c3cc2CNC1 Chemical compound CC[C@H]1Oc2cc3cccc(Cl)c3cc2CNC1 ILIQWIIQCXGTJW-GFCCVEGCSA-N 0.000 description 1
- WPVZMYOLHCEBRA-CYBMUJFWSA-N CC[C@H]1Oc2cc3cnccc3cc2CNC1 Chemical compound CC[C@H]1Oc2cc3cnccc3cc2CNC1 WPVZMYOLHCEBRA-CYBMUJFWSA-N 0.000 description 1
- MJVVSNWACQVOCY-SNVBAGLBSA-N CC[C@H]1Oc2ccc(CNN3C)c3c2CNC1 Chemical compound CC[C@H]1Oc2ccc(CNN3C)c3c2CNC1 MJVVSNWACQVOCY-SNVBAGLBSA-N 0.000 description 1
- PZGPPSUIJQJIQZ-ZZTVPSNHSA-N CC[C@H]1Oc2nc(c(C)ccc3)c3cc2CN(Cc2c(C)ccc(C(C(C)(C)C(O)=O)c(cc3)c(C)c4c3[n](C)nn4)c2)C1 Chemical compound CC[C@H]1Oc2nc(c(C)ccc3)c3cc2CN(Cc2c(C)ccc(C(C(C)(C)C(O)=O)c(cc3)c(C)c4c3[n](C)nn4)c2)C1 PZGPPSUIJQJIQZ-ZZTVPSNHSA-N 0.000 description 1
- KXZWRUQPIAZMER-YMTIKBEESA-N C[C@H](CN(Cc1cc(C(C(C)(C)C(O)=O)c(cc2)c(C)c3c2[n](C)nn3)ccc1C)CC1C2)OC1=CC(C)=C2/N=C\C=C Chemical compound C[C@H](CN(Cc1cc(C(C(C)(C)C(O)=O)c(cc2)c(C)c3c2[n](C)nn3)ccc1C)CC1C2)OC1=CC(C)=C2/N=C\C=C KXZWRUQPIAZMER-YMTIKBEESA-N 0.000 description 1
- KPHRXJZKXYRNPL-SECBINFHSA-N C[C@H](CNCc(cc1N=CCCc1c1)c1Br)O Chemical compound C[C@H](CNCc(cc1N=CCCc1c1)c1Br)O KPHRXJZKXYRNPL-SECBINFHSA-N 0.000 description 1
- AXQHSQFIBBLDJZ-UHFFFAOYSA-N NCc1c(CCCC2)c2ccc1O Chemical compound NCc1c(CCCC2)c2ccc1O AXQHSQFIBBLDJZ-UHFFFAOYSA-N 0.000 description 1
- YXEZQMYYEMGHGT-UHFFFAOYSA-N NCc1cc2ncccc2cc1O Chemical compound NCc1cc2ncccc2cc1O YXEZQMYYEMGHGT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/16—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102529 | 2019-05-31 | ||
| JPJP-P-2019-102529 | 2019-05-31 | ||
| PCT/JP2020/021426 WO2020241853A1 (ja) | 2019-05-31 | 2020-05-29 | ベンゾトリアゾール誘導体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220016124A true KR20220016124A (ko) | 2022-02-08 |
Family
ID=73553193
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217042003A Pending KR20220016124A (ko) | 2019-05-31 | 2020-05-29 | 벤조트리아졸 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12559504B2 (https=) |
| EP (1) | EP3978073B1 (https=) |
| JP (1) | JP7524899B2 (https=) |
| KR (1) | KR20220016124A (https=) |
| CN (1) | CN114174289B (https=) |
| AU (1) | AU2020283361B2 (https=) |
| BR (1) | BR112021023927A2 (https=) |
| CA (1) | CA3142295A1 (https=) |
| ES (1) | ES3047102T3 (https=) |
| MX (1) | MX2021014680A (https=) |
| WO (1) | WO2020241853A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065501T2 (hu) | 2018-08-20 | 2024-05-28 | Janssen Pharmaceutica Nv | A KEAP1-NRF2 protein-protein kölcsönhatás inhibitorok |
| CN113024399B (zh) * | 2021-03-11 | 2022-09-09 | 华东理工大学 | 药物中间体化合物及其制备方法、应用 |
| KR20230110001A (ko) * | 2022-01-14 | 2023-07-21 | 주식회사 대웅제약 | Ssglt 저해제의 합성에 유용한 중간체의 제조 방법 |
| JP7605446B2 (ja) | 2022-04-28 | 2024-12-24 | 第一三共株式会社 | ベンゾトリアゾール化合物 |
| US20250296939A1 (en) * | 2022-04-28 | 2025-09-25 | Kyoto Pharmaceutical Industries, Ltd. | Benzothiophene compound |
| WO2024262491A1 (ja) * | 2023-06-19 | 2024-12-26 | 中外製薬株式会社 | Ｎｒｆ２活性化作用を有する含窒素複素環化合物の結晶 |
| WO2025192605A1 (ja) * | 2024-03-12 | 2025-09-18 | 株式会社GALTS Pharma | 慢性腎臓病の治療薬、及び慢性腎臓病の治療薬のスクリーニング法 |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092713A1 (en) | 2013-12-18 | 2015-06-25 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203400A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016202253A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| WO2018109648A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| WO2018109646A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 compounds |
| WO2018109649A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
| WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
| WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019224667A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Indanes as nrf2 activators |
| WO2020041169A2 (en) | 2018-08-20 | 2020-02-27 | Janssen Pharmaceutica Nv | Inhibitors of keap1-nrf2 protein-protein interaction |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703456C2 (ru) | 2014-07-25 | 2019-10-17 | Тайсо Фармасьютикал Ко., Лтд. | Фенилтетрагидроизохинолиновое соединение, замещенное гетероарилом |
| WO2019116231A1 (en) * | 2017-12-11 | 2019-06-20 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| US20210177861A1 (en) | 2017-12-11 | 2021-06-17 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome |
| NZ776102A (en) | 2018-12-05 | 2024-12-20 | Scohia Pharma Inc | Macrocyclic compound and use thereof |
| JP7602469B2 (ja) * | 2019-02-15 | 2024-12-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Ｎｒｆ２活性剤としてのヒドロキシピリドキシアゼピン |
| CN114080389B (zh) | 2019-07-03 | 2024-08-30 | 千寿制药株式会社 | Nrf2活性化化合物 |
| EP4110776A1 (en) | 2020-02-28 | 2023-01-04 | Les Laboratoires Servier | New macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them |
-
2020
- 2020-05-29 MX MX2021014680A patent/MX2021014680A/es unknown
- 2020-05-29 CN CN202080055155.9A patent/CN114174289B/zh active Active
- 2020-05-29 KR KR1020217042003A patent/KR20220016124A/ko active Pending
- 2020-05-29 CA CA3142295A patent/CA3142295A1/en active Pending
- 2020-05-29 WO PCT/JP2020/021426 patent/WO2020241853A1/ja not_active Ceased
- 2020-05-29 BR BR112021023927A patent/BR112021023927A2/pt unknown
- 2020-05-29 ES ES20815167T patent/ES3047102T3/es active Active
- 2020-05-29 US US17/614,941 patent/US12559504B2/en active Active
- 2020-05-29 AU AU2020283361A patent/AU2020283361B2/en active Active
- 2020-05-29 EP EP20815167.0A patent/EP3978073B1/en active Active
- 2020-05-29 JP JP2021522912A patent/JP7524899B2/ja active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015092713A1 (en) | 2013-12-18 | 2015-06-25 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203401A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016203400A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2016202253A1 (en) | 2015-06-15 | 2016-12-22 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 regulators |
| WO2017060854A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Biaryl pyrazoles as nrf2 regulators |
| WO2017060855A1 (en) | 2015-10-06 | 2017-04-13 | Glaxosmithkline Intellectual Property Development Limited | Arylcyclohexyl pyrazoles as nrf2 regulators |
| WO2018104766A1 (en) | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | 3-(2,3-dihydro-1h-inden-5-yl)propanoic acid derivatives and their use as nrf2 regulators |
| WO2018109642A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | N-aryl pyrazoles as nrf2 regulators |
| WO2018109641A1 (en) | 2016-12-12 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-carboxylic acid pyrroles as nrf2 regulators |
| WO2018109648A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | 3-oxo-1,4-diazepinyle compounds as nrf2 activators |
| WO2018109647A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl amides as nrf2 regulators |
| WO2018109643A1 (en) | 2016-12-14 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Bisaryl heterocycles as nrf2 acti |
| WO2018109646A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Nrf2 compounds |
| WO2018109649A1 (en) | 2016-12-15 | 2018-06-21 | Glaxosmithkline Intellectual Property Development Limited | Ether linked triazoles as nrf2 regulators |
| WO2018181345A1 (ja) | 2017-03-28 | 2018-10-04 | 武田薬品工業株式会社 | 複素環化合物 |
| WO2019224667A1 (en) | 2018-05-23 | 2019-11-28 | Glaxosmithkline Intellectual Property Development Limited | Indanes as nrf2 activators |
| WO2020041169A2 (en) | 2018-08-20 | 2020-02-27 | Janssen Pharmaceutica Nv | Inhibitors of keap1-nrf2 protein-protein interaction |
Non-Patent Citations (18)
| Title |
|---|
| American Journal of Nephrology, 2018, 47, 40-47. |
| BBA Molecular Cell Research, 2018, 1865, 721-733. |
| Brain Research, 2012, 1446, 109-118. |
| Free Radical Biology and Medicine, 2013, 63, 264-273. |
| Genes and Development, 2010, 24, 1045-1058. |
| Investigative Ophthalmology & VisualScience, 2012, 53, 9, 5806-5813. |
| Journal of Clinical Investigation, 2014, 124, 2, 730-741. |
| Journal of Medicinal Chemistry, 2016, 59, 3991-4006. |
| Journal of Medicinal Chemistry, 2019, 62, 4683-4702. |
| Kidney International, 2013, 84, 1090-1095. |
| Molecular Cancer Therapeutics, 2014, 13, 12, 2968-2977. |
| Molecular Pharmacology, 2013, 84, 62-70. |
| Oxidative Medicine and Cellular Longevity, 2013, 2013, 104308. |
| Plos One, 2008, 3, 10, e3367. |
| Plos One, 4, 1, e4253. |
| Proceeding of the National Academy of Sciences of the United States of America, 2016, 113, 17, 4777-4782. |
| Scientific Reports, 2016, 6, 26585. |
| The Journal of Pharmacology and Experimantal Therapeutics, 2017, 363, 114-125. |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114174289B (zh) | 2025-03-07 |
| CA3142295A1 (en) | 2020-12-03 |
| AU2020283361A1 (en) | 2022-01-20 |
| EP3978073A4 (en) | 2023-07-12 |
| AU2020283361B2 (en) | 2025-11-27 |
| CN114174289A (zh) | 2022-03-11 |
| US12559504B2 (en) | 2026-02-24 |
| JP7524899B2 (ja) | 2024-07-30 |
| EP3978073B1 (en) | 2025-10-15 |
| MX2021014680A (es) | 2022-04-06 |
| WO2020241853A1 (ja) | 2020-12-03 |
| US20220259223A1 (en) | 2022-08-18 |
| JPWO2020241853A1 (https=) | 2020-12-03 |
| ES3047102T3 (en) | 2025-12-03 |
| EP3978073C0 (en) | 2025-10-15 |
| EP3978073A1 (en) | 2022-04-06 |
| BR112021023927A2 (pt) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20220016124A (ko) | 벤조트리아졸 유도체 | |
| CN103003233B (zh) | 新型异羟肟酸衍生物 | |
| EP3483142B1 (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
| US12286430B2 (en) | Bcl-2 inhibitor | |
| TW202200554A (zh) | 作為ｙａｐ／ｔａｚ—ｔｅａｄ蛋白—蛋白相互作用抑制劑之聯芳基衍生物 | |
| WO2021052499A1 (zh) | 稠合吡啶酮类化合物及其制备方法和应用 | |
| US9573959B2 (en) | Methods for preparing SGLT2 inhibitors | |
| EP3107908B1 (en) | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication | |
| BR112021014180A2 (pt) | Composto, medicamento, método para ativar um receptor de orexina tipo 2 em um mamífero, método para profilaxia ou tratamento de narcolepsia em um mamífero, e, uso de um composto | |
| UA125597C2 (uk) | Гетероциклічна сполука та її застосування | |
| EP3848367A1 (en) | Tricyclic compounds acting on crbn proteins | |
| TW202035424A (zh) | 大環流感內切核酸酶抑制劑 | |
| CN103539769A (zh) | 用作激酶抑制剂和hsp90抑制剂的大环化合物 | |
| CN115667226A (zh) | 作为egfr抑制剂的三环化合物 | |
| TW202039510A (zh) | 經取代的側氧基吡啶衍生物 | |
| WO2016084790A1 (ja) | ヒドロナフトキノリン誘導体 | |
| TWI902994B (zh) | Ｉｒａｋ４抑制劑、藥物組成物及其用途 | |
| WO2019185046A1 (zh) | 四元内酰胺类化合物及其药学用途 | |
| EP3851436B1 (en) | Novel heteroaromatic amide derivative and medicine containing same | |
| KR102682775B1 (ko) | 신규한 화합물의 제조방법 | |
| RU2840112C2 (ru) | Производные бензотриазола | |
| HK40068840B (zh) | 稠合吡啶酮类化合物及其制备方法和应用 | |
| HK40001145A (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
| HK40001145B (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
| HK1180673B (en) | Novel hydroxamic acid derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |